Pharmafile Logo
Pharmafocus logo
Advanced Search

HIV

Showing 15 posts of 200 posts found.

European Commission approves HIV prevention injection

August 28, 2025
Medical Communications, Research and Development European Commission, Gilead Science, HIV, HIV/AIDS, US Food and Drug Administration, World Health Organisation

The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first twice-yearly injectable medicine approved in …

News

HIV vaccine candidate successfully optimised for industrial production

October 30, 2024
Research and Development HIV, HIV/AIDS, Naobios, Sumagen, Vaccine, agreement

Sumagen Canada Inc, a biotech company based in both South Korea and Canada has partnered with CDMO Naobios to industrialise …

News

ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy

July 23, 2024
Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy

GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …

News

Gilead shares phase 3 results from HIV prevention trial

June 21, 2024
Research and Development Gilead, HIV, Infections and infestations, clinical trial

Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the …

News

Gilead and Merck share data from phase 2 trial of HIV treatment

March 7, 2024
Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …

News

ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment

February 21, 2024
Research and Development Cabenuva, HIV, HIV/AIDS, ViiV Healthcare, clinical trial, injectables

ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …

News

China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment

October 26, 2023
Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria

ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …

News
Vaccine image

ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention

July 24, 2023
Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir

GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …

News

FDA relaxes blood donation regulations for MSM

May 12, 2023
Medical Communications FDA, HIV, HIV/AIDS, blood donation

The US Food and Drug Administration (FDA) has released updated guidance for blood donation which relaxes the rules for donations …

News

GSK’s ViiV and Halozyme to collaborate on ‘ultra-long acting’ HIV drugs

June 22, 2021
Manufacturing and Production GSK, HIV, ViiV Healthcare

ViiV Healthcare, the specialist HIV company majority owned by GlaxoSmithKline (GSK), is to collaborate with Halozyme Therapeutics, giving it exclusive …

News

New HIV prevention drug application submitted to FDA

May 5, 2021
Research and Development FDA, HIV

ViiV Healthcare have initiated a rolling submission of a new drug application (NDA) with the FDA for their long-acting HIV …

News
gilead-sciences

Gilead and MSD partner to develop and commercialise two-drug HIV regimen

March 16, 2021
Manufacturing and Production Gilead, HIV, MSD

Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …

News
landing-hero-images1

ViiV presents positive long-term data for combined HIV treatment

March 8, 2021
Sales and Marketing HIV, ViiV Healthcare

ViiV Healthcare has presented positive long-term data from its global Phase IIIb ATLAS-2M study of the first complete, long-acting regimen …

News
landing-hero-images1

ViiV’s HIV drug Rukobia gets EC marketing authorisation

February 9, 2021
Manufacturing and Production HIV, ViiV

The European Commission (EC) has authorised ViiV Healthcare’s Rukobia (fostemsavir) 600mg extended-release tablets for use in combination with other antiretroviral …

News
scripps_research_web_03-18-19_t670

Scripps Research and IAVI report positive findings from HIV vaccine Phase I trial

February 4, 2021
HIV

Scripps Research and IAVI have returned positive Phase I results in their hunt for a HIV vaccine, detecting a targeted …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025